Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Merus N.V. (2GH.F)

32.60
-3.80
(-10.44%)
At close: 3:29:01 PM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
36,133
36,133
43,947
41,586
49,107
Operating Expense
308,200
308,200
200,494
201,624
139,083
Operating Income
-272,067
-272,067
-156,547
-160,038
-89,976
Net Non Operating Interest Income Expense
30,789
30,789
14,510
2,722
-129
Other Income Expense
34,103
34,103
-9,710
27,081
23,528
Pretax Income
-207,175
-207,175
-151,747
-130,235
-66,577
Tax Provision
8,151
8,151
3,192
959
239
Net Income Common Stockholders
-215,326
-215,326
-154,939
-131,194
-66,816
Diluted NI Available to Com Stockholders
-215,326
-215,326
-154,939
-131,194
-66,816
Basic EPS
-4.03
--
-3.00
-2.92
-1.73
Diluted EPS
-4.03
--
-3.00
-2.92
-1.73
Basic Average Shares
61,518.72
--
51,605.44
44,919.08
38,638.43
Diluted Average Shares
61,518.72
--
51,605.44
44,919.08
38,638.43
Total Operating Income as Reported
-272,067
-272,067
-156,547
-160,038
-89,976
Total Expenses
308,200
308,200
200,494
201,624
139,083
Net Income from Continuing & Discontinued Operation
-215,326
-215,326
-154,939
-131,194
-66,816
Normalized Income
-240,630.43
-240,630.43
-147,734.18
-150,502.32
-85,313.25
Interest Income
--
--
--
2,722
--
Interest Expense
--
--
--
--
129
Net Interest Income
30,789
30,789
14,510
2,722
-129
EBIT
-272,067
-272,067
-156,547
-160,038
-89,976
EBITDA
-269,596
-269,596
-154,007
-158,753
-88,491
Reconciled Depreciation
2,471
2,471
2,540
1,285
1,485
Net Income from Continuing Operation Net Minority Interest
-215,326
-215,326
-154,939
-131,194
-66,816
Total Unusual Items Excluding Goodwill
34,103
34,103
-9,710
26,022
24,663
Total Unusual Items
34,103
34,103
-9,710
26,022
24,663
Normalized EBITDA
-303,699
-303,699
-144,297
-184,775
-113,154
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
8,798.57
8,798.57
-2,505.18
6,713.68
6,165.75
12/31/2021 - 5/7/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2BO.F Serina Therapeutics Inc. R
5.10
+10.87%
 
ZA71.F Larimar Therapeutics, Inc.
1.9400
-6.73%
 
PCJ.F Abeona Therapeutics Inc.
4.5000
-2.17%
 
DRUG.CN Bright Minds Biosciences Inc.
47.48
0.00%
 
NEXI NexImmune, Inc.
0.0001
0.00%
 
SER Serina Therapeutics, Inc.
6.09
+5.36%
 
CRGX CARGO Therapeutics, Inc.
4.5250
-0.55%
 
CTNM Contineum Therapeutics, Inc.
4.5200
-4.64%
 
VALN Valneva SE
6.99
+1.75%
 
SION Sionna Therapeutics, Inc.
12.60
-3.74%